BioLineRX
BLRX
22 hedge funds and large institutions have $7.3M invested in BioLineRX in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 4 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
12% less funds holding
Funds holding: 25 → 22 (-3)
18% less capital invested
Capital invested by funds: $8.87M → $7.3M (-$1.57M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$335K |
| 2 |
Morgan Stanley
New York
|
+$67.1K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$33.5K |
| 4 |
Jane Street
New York
|
+$16.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$134K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$36.7K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$13K |
| 5 |
WSCM
Wellington Shields Capital Management
New York
|
-$11K |
BLRX Hedge Fund Activity: Q4 2016 in Review
22 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2016, worth a combined $7.3M — down 18% from $8.87M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BLRX and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Senvest Management, adding an estimated $335K. The largest seller was Virtu KCG Holdings, cutting an estimated $134K.
- 22 institutional investors held BioLineRX (BLRX) as of Q4 2016, down from 25 in Q3 2016.
- Funds reported $7.3M of BioLineRX stock for Q4 2016, down 18% quarter-over-quarter.
- 1 fund opened new BioLineRX positions in Q4 2016 and 4 closed out, a net change of -3 holders.
- The largest BioLineRX buyer in Q4 2016 was Senvest Management, an estimated $335K added.
- The largest BioLineRX seller in Q4 2016 was Virtu KCG Holdings, an estimated $134K sold.
Based on aggregated 13F filings for Q4 2016.